Protara Therapeutics, Inc. Unrealized Gain (Loss) on Derivatives
Protara Therapeutics, Inc. (TARA) reported Unrealized Gain (Loss) on Derivatives of -$81.00 thousand for the 9-month period ending 2014-09-30, per its 10-Q filed 2014-11-25.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2014-11-25
- 2014-09-30: Unrealized Gain (Loss) on Derivatives 9 month -$81.00K.
- 2013-09-30: Unrealized Gain (Loss) on Derivatives 9 month -$20.00K.
| Period end | Unrealized Gain (Loss) on Derivatives 9 month |
|---|---|
| 2014-09-30 | -$81.00K 10-Q · filed 2014-11-25 |
| 2013-09-30 | -$20.00K 10-Q · filed 2014-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |